Article Text

PDF

SAT0209 Characterization of pure membranous lupus nephritis: A cohort of 134 patients
  1. L. Silva1,
  2. T. Otόn1,
  3. A. Askanase2,
  4. P. Carreira3,
  5. E. Rodríguez-Almaraz3,
  6. J. Lόpez-Longo4,
  7. I. Rúa-Figueroa5,
  8. J. Narváez6,
  9. E. Ruiz7,
  10. E. Calvo8,
  11. F. Toyos9,
  12. J.J. Alegre10,
  13. E. Tomero11,
  14. C. Montilla12,
  15. A. Zea13,
  16. E. Uriarte14,
  17. C. Marras15,
  18. V. Martínez-Taboada16,
  19. Ά. Belmonte17,
  20. J. Rosas18,
  21. E. Raya19,
  22. G. Bonilla20,
  23. M. Freire21,
  24. J. Calvo22
  1. 1H Puerta de Hierro, Madrid, Spain
  2. 2H Joint Diseases, New York, United States
  3. 3H 12 Octubre
  4. 4H Gregorio Marañόn, Madrid
  5. 5H Dr Negrín, Las Palmas
  6. 6H Bellvitge, L’Hospitalet
  7. 7H Basurto, Bilbao
  8. 8H Infanta Sofía, S Sebastián de los Reyes
  9. 9H Virgen Macarena, Sevilla
  10. 10H Dr Peset, Valencia
  11. 11H La Princesa, Madrid
  12. 12H Salamanca, Salamanca
  13. 13H Ramόn y Cajal, Madrid
  14. 14H Donostia, S Sebastián
  15. 15H Virgen Arrixaca, Murcia
  16. 16H Marqués de Valdecilla, Santander
  17. 17H Carlos Haya, Málaga
  18. 18H Marina Baixa, Villajoyosa
  19. 19H San Cecilio, Granada
  20. 20H La Paz, Madrid
  21. 21H Juan Canalejo, A Coruña
  22. 22H Sierrallana, Torrelavega, Spain

Abstract

Background Few studies and small series have addressed the characteristics of pure membranous lupus nephritis (MLN).

Objectives To establish the clinical characteristics, treatment and prognosis of MLN and to make international and intersocial comparisons.

Methods Twenty-one Spanish centres and 1 in the US participated in the study. All SLE patients with biopsy proven MLN were included. Data on clinical and laboratory features, prescribed drugs, renal outcomes and survival were collected. Descriptive statistics were used to describe the main features of the series. Chi-squared distribution and Fisher test were use to analyse categorical variables and the U Mann-Whitney test for quantitative variable. A p value <0.05 was considered significant.

Results 134 patients were included (see table). Female sex (.036), a low basal serum creatinine (BSC) (0.92 Vs 1.53 mg/dl; <0.001) and previous treatment with azathioprine (AZA) (.046) were predictors of a final proteinuria <1 g. US patients (0.042), patients without a Health coverage (0.033), with previous venous thrombosis (0.037) and those who had not received chloroquine (0.011) or AZA (0.028) for MLN had less chances of achieving a final proteinuria <0.5 g. Patients with final doubled creatinine had a greater initial 24 h-proteinuria (7.73 Vs 4.37 g; 0.04) and a lower creatinine clearance (CCr) (64 Vs 109 ml/min; .032). Moreover, male sex (<0.001), basal high blood pressure (0.028), chronic cardiopathy (0.003), peripheral (0.005) or cerebral artheriopathy (.02), and not having received anticoagulant treatment were risk factors for doubling BSC. End-stage renal disease was predicted by male sex (0.009), HBP (0.019), dyslipidemia (0.002), high basal 24 h-proteinuria (8.80 Vs 4.36 g; 0.03), high BSC (2.76 Vs 0.91 mg/dl; <0.001) and a low CCr (31 Vs 108 ml/min; 0.001).

Conclusions MLN usually begins with nephrotic syndrome, high proteinuria and normal BSC. Its prognosis is favourable in maintaining renal function although proteinuria usually persists over time. Cardiovascular disease and some socio-sanitary factors are related with bad prognosis.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.